By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Transgenomic announced today it has entered into definitive agreements to raise about $22 million in a private placement.

The deal is with institutional and other accredited investors and as part of it, the Omaha, Neb.-based firm will issue an aggregate of 19 million shares of its stock at $1 per share and five-year warrants to purchase up to an aggregate of 9.5 million shares of Transgenomic stock at an exercise price of $1.25 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.